Drugs / [212Pb]VMT01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05655312 | Jun 2023 → Dec 2027 expected | cutaneous melanoma, metastatic melanoma | Perspective Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Perspective Therapeutics | Results Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma perspectivetherapeutics.com ↗
One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026 |
| 2023-05-24 | Perspective Therapeutics | Results Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) perspectivetherapeutics.com ↗
In conclusion: When combined with dual ICIs, low doses of [212Pb]VMT01 was more efficacious and resulted in complete tumor remission when compared with mid- and high-administered radioactivity doses. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-02 | Perspective Therapeutics | Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 perspectivetherapeutics.com ↗ |
| 2026-05-21 | Perspective Therapeutics | Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma perspectivetherapeutics.com ↗ |
| 2025-09-15 | Perspective Therapeutics | Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma perspectivetherapeutics.com ↗ |
| 2023-05-24 | Perspective Therapeutics | Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) perspectivetherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [212Pb]VMT01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05655312 ↗ |
| Route | Intravenous | “[212Pb]VMT01 administered IV every 8 weeks” NCT05655312 ↗ |
| Target | MC1R | “[212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R)” NCT05655312 ↗ |